US top court says FDA preempts state liability laws for defective generic drugs
This article was originally published in SRA
Executive Summary
The US Supreme Court on 24 June clamped down on lawsuits filed by patients claiming injuries from design defects in generic drugs, with the 5-4 majority of the court declaring that Food and Drug Administration approval preempts a state's liability laws – handing a major legal win to the pharmaceutical industry1.